請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67490
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林珍芳(ZHEN-FANG LIN) | |
dc.contributor.author | Wei Ho | en |
dc.contributor.author | 何暐 | zh_TW |
dc.date.accessioned | 2021-06-17T01:34:30Z | - |
dc.date.available | 2022-09-08 | |
dc.date.copyright | 2017-09-08 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-02 | |
dc.identifier.citation | 1. Assimes TL, Elstein E, Langleben A, Suissa S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiology and drug safety. 2008;17(11):1039-1049.
2. Fryzek JP, Poulsen AH, Lipworth L, et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast cancer research and treatment. 2006;97(3):231-236. 3. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628-638. 4. Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2013;24(7):1721-1730. 5. Haux J, Klepp O, Spigset O, Tretli S. Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer. 2001;1:11-11. 6. Ahern TP, Lash TL, Sorensen HT, Pedersen L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast cancer research : BCR. 2008;10(6):R102. 7. Biggar RJ, Wohlfahrt J, Oudin A, Hjuler T, Melbye M. Digoxin use and the risk of breast cancer in women. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(16):2165-2170. 8. Platz EA, Yegnasubramanian S, Liu JO, et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer discovery. 2011;1(1):68-77. 9. Sjoberg T, Garcia Rodriguez LA, Lindblad M. Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2007;5(10):1160-1166.e1161. 10. Ronquist G, Rodríguez LAG, Ruigómez A, et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. The Prostate. 2004;58(1):50-56. 11. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. The Lancet Oncology. 2010;11(7):627-636. 12. Pasternak B, Svanstrom H, Callreus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123(16):1729-1736. 13. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. Journal of hypertension. 2011;29(4):623-635. 14. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(19):2635-2644. 15. Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecologic oncology. 2012;127(2):375-378. 16. Wang HM, Liao ZX, Komaki R, et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2013;24(5):1312-1319. 17. Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. European urology. 2014;65(3):635-641. 18. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast cancer research and treatment. 2011;129(2):549-556. 19. Lemeshow S, Sorensen HT, Phillips G, et al. beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011;20(10):2273-2279. 20. Choi CH, Song T, Kim TH, et al. Meta-analysis of the effects of beta blocker on survival time in cancer patients. Journal of cancer research and clinical oncology. 2014;140(7):1179-1188. 21. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (London, England). 2011;377(9759):31-41. 22. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (London, England). 2010;376(9754):1741-1750. 23. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet (London, England). 2012;379(9826):1591-1601. 24. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet (London, England). 2007;369(9573):1603-1613. 25. González-Pérez A, García Rodríguez LA, López-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer. 2003;3(1):28. 26. Li X, Wu XB, Chen Q. Statin use is not associated with reduced risk of skin cancer: a meta-analysis. British Journal of Cancer. 2014;110(3):802-807. 27. Tan M, Song X, Zhang G, et al. Statins and the Risk of Lung Cancer: A Meta-Analysis. PLoS ONE. 2013;8(2):e57349. 28. Cholesterol Treatment Trialists C. Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy. PLOS ONE. 2012;7(1):e29849. 29. Bansal D, Undela K, D'Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7(10):e46691. 30. Jespersen CG, Norgaard M, Friis S, Skriver C, Borre M. Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997-2010. Cancer epidemiology. 2014;38(1):42-47. 31. Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotropic effects of statins. Indian Journal of Endocrinology and Metabolism. 2015;19(5):554-562. 32. Group TL-TIwPiIDS. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. New England Journal of Medicine. 1998;339(19):1349-1357. 33. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology (Cambridge, Mass). 2002;13(3):262-267. 34. Sacks FM, Pfeffer MA, Moye LA, et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. New England Journal of Medicine. 1996;335(14):1001-1009. 35. May MB, Glode A. Novel Uses for Lipid-Lowering Agents. Journal of the Advanced Practitioner in Oncology. 2016;7(2):181-187. 36. Liao JK. Safety and Efficacy of Statins in Asians. The American journal of cardiology. 2007;99(3):410-414. 37. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clinical pharmacology and therapeutics. 2005;78(4):330-341. 38. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 2016;66(1):7-30. 39. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. European journal of cancer (Oxford, England : 1990). 2010;46(17):3040-3052. 40. Cancer Facts & Figures 2016. Atlanta, Ga: American Cancer Society. American Cancer Society. 2016. 41. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16(11):2213-2217. 42. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British journal of clinical pharmacology. 2009;67(1):99-109. 43. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer research. 2011;71(5):1763-1771. 44. Murtola TJ, Tammela TL, Maattanen L, et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. International journal of cancer. 2010;127(7):1650-1659. 45. Morote J, Celma A, Planas J, et al. Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness. International Journal of Molecular Sciences. 2014;15(8):13615-13623. 46. Platz EA, Tangen CM, Goodman PJ, et al. Statin Drug Use Is Not Associated with Prostate Cancer Risk in Men who are Regularly Screened. The Journal of urology. 2014;192(2):379-384. 47. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin Drugs and Risk of Advanced Prostate Cancer. JNCI: Journal of the National Cancer Institute. 2006;98(24):1819-1825. 48. Lustman A, Nakar S, Cohen AD, Vinker S. Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study. Prostate cancer and prostatic diseases. 2014;17(1):6-9. 49. Freedland SJ, Hamilton RJ, Gerber L, et al. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate cancer and prostatic diseases. 2013;16(3):254-259. 50. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16(11):2218-2225. 51. Chan JM, Litwack-Harrison S, Bauer SR, et al. Statin use and risk of prostate cancer in the prospective Osteoporotic Fractures in Men (MrOS) Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21(10):1886-1888. 52. Kantor ED, Lipworth L, Fowke JH, Giovannucci EL, Mucci LA, Signorello LB. Statin use and risk of prostate cancer: results from the Southern Community Cohort Study. The Prostate. 2015;75(13):1384-1393. 53. Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98(2):204-208. 54. CDC/NCHS, National Health and Nutrition Examination Survey, 2003–2012. 55. SEER Cancer Statistics Review, 1973-1999 http://seer.cancer.gov/csr/1973_1999/ (Accessed on February 20, 2017). 56. Hankey BF FE, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. Journal of the National Cancer Institute. 1999;91(12):2017. 57. Delongchamps NB SA, Haas GP The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006;13(3):158. 58. Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. Journal of the National Cancer Institute. 1991;83(8):551-557. 59. Ingles SA, Coetzee GA, Ross RK, et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer research. 1998;58(8):1620-1623. 60. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. Journal of the National Cancer Institute. 2000;92(24):2009-2017. 61. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer. 2003;97(8):1894-1903. 62. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. International journal of cancer. 2003;107(5):797-803. 63. Hemminki K, Czene K. Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer. 2002;95(6):1346-1353. 64. Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. JNCI: Journal of the National Cancer Institute. 2016;108(10):djw110-djw110. 65. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. The Prostate. 1990;17(4):337-347. 66. Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. European urology. 2015;68(2):186-193. 67. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(14):1748-1757. 68. Edwards SM, Evans DG, Hope Q, et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer. 2010;103(6):918-924. 69. Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15(3):1112-1120. 70. Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer. 2008;98(2):502-507. 71. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910-919. 72. Sinha R, Park Y, Graubard BI, et al. Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States. American journal of epidemiology. 2009;170(9):1165-1177. 73. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. Journal of the National Cancer Institute. 1999;91(5):414-428. 74. Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ. Prospective study of plasma fatty acids and risk of prostate cancer. Journal of the National Cancer Institute. 1994;86(4):281-286. 75. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer. 2001;85(11):1700-1705. 76. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (London, England). 2008;371(9612):569-578. 77. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. European urology. 2013;63(5):800-809. 78. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17(8):989-1003. 79. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer prevention research (Philadelphia, Pa). 2011;4(4):486-501. 80. Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. European urology. 2014;66(6):1054-1064. 81. Murphy AB, Akereyeni F, Nyame YA, et al. Smoking and prostate cancer in a multi-ethnic cohort. The Prostate. 2013;73(14):1518-1528. 82. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. Journal of the National Cancer Institute. 2005;97(13):975-980. 83. Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer journal (Sudbury, Mass). 2006;12(2):130-135. 84. Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. International journal of cancer. 2003;106(3):409-415. 85. Salinas CA, Kwon EM, FitzGerald LM, et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. American journal of epidemiology. 2010;172(5):578-590. 86. Thompson IM, Jr., Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369(7):603-610. 87. Survival in the Prostate Cancer Prevention Trial. New England Journal of Medicine. 2013;369(20):1967-1968. 88. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202. 89. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60(1):78-83. 90. Stark JR, Judson G, Alderete JF, et al. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. Journal of the National Cancer Institute. 2009;101(20):1406-1411. 91. Sutcliffe S, Giovannucci E, Alderete JF, et al. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(5):939-945. 92. Network. NCC. Prostate cancer (Version I.2017). 93. Wejde J, Hjertman M, Carlberg M, et al. Dolichol-like lipids with stimulatory effect on DNA synthesis: substrates for protein dolichylation? Journal of cellular biochemistry. 1998;71(4):502-514. 94. Denoyelle C, Vasse M, Korner M, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001;22(8):1139-1148. 95. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cells. Journal of Clinical Investigation. 2001;108(3):399-405. 96. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. Journal of Clinical Investigation. 2001;108(3):391-397. 97. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature medicine. 2000;6(9):1004-1010. 98. Vincent L, Soria C, Mirshahi F, et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arteriosclerosis, thrombosis, and vascular biology. 2002;22(4):623-629. 99. Vincent L, Chen W, Hong L, et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS letters. 2001;495(3):159-166. 100. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105(6):739-745. 101. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999;5(8):2223-2229. 102. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leukemia & lymphoma. 2000;40(1-2):167-178. 103. Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM. Statins and prostate cancer diagnosis and grade in a veterans population. Journal of the National Cancer Institute. 2011;103(11):885-892. 104. Breau RH, Karnes RJ, Jacobson DJ, et al. The association between statin use and the diagnosis of prostate cancer in a population based cohort. The Journal of urology. 2010;184(2):494-499. 105. Chang CC, Ho SC, Chiu HF, Yang CY. Statins increase the risk of prostate cancer: a population-based case-control study. The Prostate. 2011;71(16):1818-1824. 106. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004;90(3):635-637. 107. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Jr., Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiology and drug safety. 2008;17(1):27-36. 108. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(12):2388-2394. 109. Boudreau DM, Yu O, Buist DS, Miglioretti DL. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control. 2008;19(7):767-774. 110. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Archives of internal medicine. 2000;160(15):2363-2368. 111. Haukka J, Sankila R, Klaukka T, et al. Incidence of cancer and statin usage--record linkage study. International journal of cancer. 2010;126(1):279-284. 112. National Health Insurance Administration MoHaW, Taiwan, R.O.C. National Helath Insurance Annual Report 2014-2015. 2014. 113. Li YH, Ueng KC, Jeng JS, et al. 2017 Taiwan lipid guidelines for high risk patients. Journal of the Formosan Medical Association = Taiwan yi zhi. 2017;116(4):217-248. 114. Ji MS, Jeong MH, Ahn Yk, et al. Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis. International Journal of Cardiology.225:50-59. 115. Tan N, Klein EA, Li J, Moussa AS, Jones JS. Statin use and risk of prostate cancer in a population of men who underwent biopsy. The Journal of urology. 2011;186(1):86-90. 116. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16(11):2226-2232. 117. Murtola TJ, Tammela TLJ, Lahtela J, Auvinen A. Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study. Cancer Epidemiology Biomarkers & Prevention. 2007;16(11):2226-2232. 118. Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (London, England). 2015;385(9976):1397-1405. 119. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. International journal of cancer. 2008;123(4):899-904. 120. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. European journal of cancer (Oxford, England : 1990). 2008;44(15):2122-2132. 121. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. American journal of epidemiology. 2005;162(4):318-325. 122. Fowke JH, Motley SS, Barocas DA, et al. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer causes & control : CCC. 2011;22(3):417-426. 123. Stein EA, Corsini A, Gimpelewicz CR, Bortolini M, Gil M. Fluvastatin treatment is not associated with an increased incidence of cancer. International journal of clinical practice. 2006;60(9):1028-1034. 124. Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacological reviews. 2012;64(1):102-146. 125. Solomon KR, Freeman MR. The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am. 2011;38. 126. Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure. An updated review. Clinical pharmacokinetics. 1988;15(2):94-113. 127. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation. 2016;133(11):1104-1114. 128. John F. C. Sung Ph.D. RSLMD, Dr.P.H.,Yeong-Shiau Pu M.D., Ph.D.,Yi-Chun Chen M.S.,Hong C. Chang M.D.,Ming-Kuen Lai M.D. Risk factors for prostaet carcinoma in Taiwan. Cancer. 1999;86(3):484-491. 129. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014;130(25):e344-e426. 130. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004;110(5):588-636. 131. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European heart journal. 2016;37(3):267-315. 132. Latry P, Molimard M, Dedieu B, Couffinhal T, Begaud B, Martin-Latry K. Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC cardiovascular disorders. 2011;11:46. 133. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. The Annals of pharmacotherapy. 2010;44(9):1410-1421. 134. Schatzkin A, Hoover RN, Taylor PR, et al. Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer research. 1988;48(2):452-458. 135. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. Jama. 1992;267(1):70-76. 136. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1997;6(11):863-873. 137. Hiroyasu Iso AI, Manami Inoue,Shinichi Sato,Shoichiro Tsugane. Serum cholesterol levels in relation to the incidence of cancer: The JPHC study cohorts. International journal of cancer. 2009;125(11):2679-2686. 138. Platz EA, Till C, Goodman PJ, et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18(11):2807-2813. 139. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010;21(1):61-68. 140. Health Promotion Administration MoHaW. Taiwan Cancer Registry (Available at: http://www.hpa.gov.tw/Home/Index.aspx). 141. McKenney JM. Pharmacologic characteristics of statins. Clinical cardiology. 2003;26(4 Suppl 3):Iii32-38. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67490 | - |
dc.description.abstract | 背景:過去關於statins的使用與攝護腺癌風險之間關係的研究大多都是以西方族群為研究對象,且得到不一致的結果。
目的:分析台灣statins的使用與攝護腺癌風險之間的關係,以及不同特性的statins對攝護腺癌風險之影響。 方法:本研究為一個回溯性的觀察性世代研究,取材自2000年1月至2013年12月健保資料庫資料。男性保險人在2001年1月至2008年12月之間,被新診斷急性冠心症且已滿55歲以上,以及在指標日期前或後180天內沒有任何癌症的診斷且在指標日期前180天無statins的使用者,會被納入本研究分析。傾向分數會被用來配對statins的使用者與非使用者,時間相依共變相存活分析會被用來分析使用者與非使用者的攝護腺癌的風險。我們會分析病人直到最早的攝護腺癌發生、退保或直到研究結束(2013年12月31日)。 結果:經過一比一傾向分數配對後,共26,628位男性被納入研究。相較於非statins使用族群,使用者有較低的攝護腺癌風險(HR: 0.719, 95% CI: 0.570-0.908),在晚期攝護腺癌風險上亦有統計上的顯著差異(HR: 0.718, 95% CI: 0.530-0.972)。相較於沒有使用statins,累積標準化定義之每日劑量(cDDD)在84以下之使用者,其風險比為1.241 (0.931-1.654),cDDD介於84與312者,其風險比為1.203 (0.903-1.604),cDDD介於818與312者,其風險比為0.712 (0.513-0.989),cDDD大於818者,其風險比為0.426 (0.298-0.609)。在不同的statins中,simvastatin、fluvastatin、atorvastatin和rosuvastatin可以分別下降攝護腺癌風險26. 6% (HR: 0.734, 95% CI: 0.552-0.976)、30.2% (HR: 0.698, 95% CI: 0.490-0.995)、30.9% (HR: 0.691, 95% CI: 0.537-0.889)、37.8% (HR: 0.622, 95% CI: 0.453-0.853)。使用脂溶性statins的人其攝護腺癌風險並無比水溶性statins來的低(HR: 0.916, 95% CI: 0.570-1.472)。然而,高強度statins使用者比非使用者,攝護腺的風險有顯著的下降 (HR: 0.548, 95% CI: 0.367-0.820)。 結論:在台灣的急性冠心症族群中,statins的使用者有較低的攝護腺癌風險,且隨著statins暴露的增加,其風險可能越低,尤其是simvastatin、fluvastatin、atorvastatin、rosuvastatin。 | zh_TW |
dc.description.abstract | Background: Literature studying statins use and the risk of prostate cancer were mainly done in western countries and yielded inconsistent results.
Objective: First, to analyze the statins effects on the risk of prostate cancer in Taiwan. Second, to access whether different characteristics of statins will affect the risk of prostate cancer differently. Methods: This is a retrospective cohort study using National Health Insurance Research Database from January 1, 2000 to December 31, 2013. Patients aged more than 55 and were newly diagnosed with acute coronary syndrome between January 1, 2001 to December 31, 2008 without any cancers diagnosis before or 180 days after index date were included. The propensity score was used to match statin users and non-users. Time-dependent Cox hazards regression model was used to calculate the risk of prostate cancer between drug exposure group and non-exposure group. The analyses were also stratified to assess the statins effect in different age groups, the severity of underline diseases, comorbidities, and hospital levels. The follow-up period was the time from index date to the outcome of interests, withdraw from the registry, and the end of study (2013.12.31). Results: After 1:1 propensity score matching, a total of 26,628 men were included. Statin use was associated with significantly lower risk of both total and advanced prostate cancer (Adjusted HR: 0.719, 95% CI: 0.570-0.908; Adjusted HR: 0.718, 95% CI: 0.530-0.972 respectively). Compared with statins non-users, the adjusted HR (95% CI) were 1.328 (0.931-1.654) for the group with cumulative dose <84 cDDD, 1.203 (0.903-1.604) for the group 312>cDDD≧84, 0.712 (0.513-0.989) for the group 818>cDDD≧312, and 0.426 (0.298-0.609) for the group cDDD≧818. Simvastatin, fluvastatin, atorvastatin, and rosuvastatin users showed significant 26.6%, 30.2%, 30.9%, and 37.8% reductions in total prostate cancer risk respectively. Lipophilic statins were not different from hydrophilic statins in total and advanced prostate cancer risk (Adjusted HR: 1.014, 95% CI: 0.638-1.610; Adjusted HR: 0.806, 95% CI: 0.445-1.459). However, high-intensity statins showed a significant reduction in total and advanced prostate cancer risk compared with statins non-users (Adjusted HR: 0.548, 95% CI:0.367-0.820; Adjusted HR: 0.487, 95% CI: 0.284-0.836). Conclusions: In Taiwan ACS population, reduction in risk of prostate cancer were observed in statin users, especially patients used simvastatin, fluvastatin, atorvastatin, rosuvastatin or high-intensity statins. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:34:30Z (GMT). No. of bitstreams: 1 ntu-106-R04451004-1.pdf: 1776120 bytes, checksum: 857bfaa5750d4bc5fefcfb4e0e488e4f (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii Abstract iv List of Figures viii List of Tables ix Chapter 1 Introduction 1 1.1 Background 1 1.2 Study Aims 2 1.3 Significance of the study 3 Chapter 2 Literature Review 4 2.1 Epidemiology 4 2.1.1 Prostate Cancer 4 2.1.2 Statins Use 4 2.2 Risk Factors of Prostate Cancer 4 2.2.1 Age 4 2.2.2 Ethnicity 5 2.2.3 Genetic Factors 5 2.2.4 Diets 6 2.2.5 Obesity 6 2.2.6 Physical Activity 6 2.2.7 Smoking 6 2.2.8 Drugs 7 2.2.9 Disease 8 2.3 Treatment of Prostate Cancer 9 2.3.1 Grading and Staging 9 2.3.2 Treatments 9 2.4 Mechanism of Prostate Cancer Prevention of Statin 9 2.4.1 Inhibition of Tumor Cell Growth 9 2.4.2 Inhibition of Angiogenesis 10 2.4.3 Induction of Apoptosis 10 2.5 Clinical Evidence 10 2.5.1 Total Prostate Cancer 10 2.5.2 Advanced Prostate Cancer 11 Chapter 3 Methods 13 3.1 Data Source 13 3.2 Study Population 13 3.2.1 Inclusion Criteria 13 3.2.2 Exclusion Criteria 14 3.3 Study Design 14 3.4 Exposure Assessment 15 3.5 Outcome Measurements 16 3.6 Statistical Analysis 16 3.7 Sensitivity Analysis 17 Chapter 4 Results 18 4.1 Overview of the study cohort enrollment 18 4.2 Aim 1: To assess the statin effects on the risk of prostate cancer in Taiwan. 18 4.2.1 Baseline characteristics 18 4.2.2 Statin use and the risk of prostate cancer 19 4.2.3 Statin exposure and the risk of prostate cancer 19 4.3 Aim 2: To analyze which types of statins have more impact on the risk of prostate cancer in Taiwan. 20 4.3.1 Statin types and the risk of prostate cancer 20 4.3.2 Lipophilicity of statin and the risk of prostate cancer 21 4.3.3 Intensity of statins and the risk of prostate cancer 21 4.4 Subgroup analysis 21 4.5 Sensitivity analysis 22 Chapter 5 Discussion 24 5.1 Summary of results 24 5.2 Interpretations 24 5.2.1 Aim 1: Statin use and the risk of prostate cancer in Taiwan 24 5.2.2 Aim 2: Different types of statin use and the risk of prostate cancer in Taiwan 26 5.2.3 Subgroup analysis 29 5.2.4 Sensitivity analysis 29 5.3 Strengths and limitations 30 Chapter 6 Conclusions 33 Figures 34 Tables 39 References 62 | |
dc.language.iso | en | |
dc.title | 臺灣急性冠心症病人使用Statins與攝護腺癌的風險 | zh_TW |
dc.title | Statins Use and the Risk of Prostate Cancer in Acute Coronary Syndrome Patients in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 簡國龍(KUO-LIONG CHIEN),蕭斐元(Fei-yuan Hsiao) | |
dc.subject.keyword | Statins,亞洲,急性冠心症,攝護腺癌, | zh_TW |
dc.subject.keyword | Statins,Asian,Acute coronary syndrome,Prostate cancer,NHIRD, | en |
dc.relation.page | 73 | |
dc.identifier.doi | 10.6342/NTU201702337 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-02 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 1.73 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。